Accessibility Skip to:
  • Accessibility Policy
  • Main Content
  • Main Menu
  • Contact

  • -A: Font Smaller
  • +A: Font Larger
  • Reset Font
  • High Contrast
  • Low Contrast
  • Reset Contrast
History:
You are here:
  • Grand Challenges Canada
  • >
  • Innovations
  • >
  • 0452-01
  • Français
  • Get to Know Us
    • Who We Are
    • Co-CEOs
    • Governance
    • Accountability
    • The Team
    • Partnerships
    • Career Opportunities
    • Service Opportunities
    • Contact Us
  • Learn What We Do
    • What We Do
    • Global Health
    • Humanitarian
    • Indigenous
    • Transition To Scale
    • Innovative Financing
    • Innovations & Results
    • Annual Report
  • Apply for Funding
    • Funding Opportunities
    • Innovator Resources
    • Gender Equality Portal
  • Get Informed
    • News and Media
    • Blog
    • Publications
    • Subscribe
    • Photos and Videos
Grand Challenges Canada

Bold Ideas with Big Impact®

Browse our Innovations and Results
  • Get to Know Us
    • Who We Are
    • Co-CEOs
    • Governance
    • Accountability
    • The Team
    • Partnerships
    • Career Opportunities
    • Service Opportunities
    • Contact Us
  • Learn What We Do
    • What We Do
    • Global Health
    • Humanitarian
    • Indigenous
    • Transition To Scale
    • Innovative Financing
    • Innovations & Results
    • Annual Report
  • Apply for Funding
    • Funding Opportunities
    • Innovator Resources
    • Gender Equality Portal
  • Get Informed
    • News and Media
    • Blog
    • Publications
    • Subscribe
    • Photos and Videos
  • Accessibility
  • Contact
  • Français

Home » Innovations » 0452-01

Immunotherapy of tuberculosis

FacebookTwitterLinked In

Start Date: 01/10/2013- End Date: 31/03/2015


Project Lead(s): Dmytro Butov

Issue

After AIDS, tuberculosis (TB) is the most important cause of death from an infectious agent.

Current TB drugs are not effective against multidrug-resistant TB (MDR-TB) and TB associated with HIV, and require long courses of therapy at high cost.

Solution

The goal of this project was to conduct a clinical trial to confirm or refute earlier published findings that suggested Immunoxel lozenges, given with TB treatment, improve patient outcomes.

Immunoxel is a low-cost, multi-herbal product manufactured by Ekomed Company (Kiev, Ukraine) that is sold over the counter in almost every pharmacy in Ukraine, as a dietary immunomodulatory supplement.

About 15 years ago, Ukrainian doctors accidentally discovered that, when Immunoxel was used along with TB drugs, it cut down TB treatment time, increased bacillary clearance rate and lowered hepatotoxicity of TB drugs. The efficacy was the same regardless of the type of TB or whether TB existed in the presence of HIV.

The aim of the project was to reproduce Immunoxel results in a larger group of TB patients (n = 360) and to determine whether the outcome of such an intervention would be superior or inferior to ‘sham’ or placebo lozenges without Immunoxel.

Outcome

Statistical analysis revealed that Immunoxel lozenges produced the clearance of TB bacilli in 65.9% of treated patients, versus 28.8% in the control or placebo group – a highly statistically significant difference.

In addition, two important advantages of the approach, which must be emphasized, were revealed.

First, the time to bacterial clearance was just one month – lightning-fast, compared to the up to two years required to treat MDR-TB patients.

Second, Immunoxel appears to have an equally potent effect regardless of gravity of the disease, meaning that drug-sensitive TB as well as difficult-to-treat resistant strains responded to treatment in the same manner.

Knowledge of the project has been disseminated in conferences and publications.

The project team will be applying for Phase II Transition To Scale funding to help with initiating the commercialization process.

The team feels that, within three years, commercialization of Immunoxel as an immunomodulating supplement, to be given together with standard TB drugs, could result in helping treat 11 million TB patients in six countries where the lozenges are already approved.

Stay in touch with this innovator

  • Organization Website
  • Network Website
  • Innovation Overview
    Program

    Stars in Global Health

    Institution

    EcoMed, HTM LLC

    Institution Country

    Mongolia

    Implementation Country

    Mongolia, South Africa, Ukraine

    Implementation Region

    East Asia and Pacific

    Priority

    Infectious Diseases, Tuberculosis

    Platform

    Drug

Grand Challenges Canada’s programs are primarily undertaken with the financial support of the Government of Canada provided through Global Affairs Canada.

Government of Canada
  • Fluxx Technical Support
  • Privacy Policy
  • Website Legal Terms and Disclaimer
We use cookies on our website to give you the most relevant experience by remembering your preferences and activity on our website. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may click on "Cookie Settings" to select the cookies applicable to your activity and disable those that do not. Please note that you will not be able to disable all cookies as some are necessary for the functioning of the website.
Cookie SettingsAccept All
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT